241 related articles for article (PubMed ID: 19106650)
1. To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma.
Lim HY; Thiel E; Glantz MJ
Curr Opin Oncol; 2008 Sep; 20(5):495-501. PubMed ID: 19106650
[TBL] [Abstract][Full Text] [Related]
2. Secondary central nervous system lymphoma: risk factors and prophylaxis.
Montoto S; Lister TA
Hematol Oncol Clin North Am; 2005 Aug; 19(4):751-63, viii. PubMed ID: 16083835
[TBL] [Abstract][Full Text] [Related]
3. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.
Herrlinger U; Glantz M; Schlegel U; Gisselbrecht C; Cavalli F
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S25-34. PubMed ID: 19660681
[TBL] [Abstract][Full Text] [Related]
4. Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.
Mazhar D; Stebbing J; Bower M
Expert Rev Anticancer Ther; 2006 Mar; 6(3):335-41. PubMed ID: 16503851
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
Bierman P; Giglio P
Hematol Oncol Clin North Am; 2005 Aug; 19(4):597-609, v. PubMed ID: 16083825
[TBL] [Abstract][Full Text] [Related]
6. Treatment and prevention of secondary CNS lymphoma.
Nagpal S; Glantz MJ; Recht L
Semin Neurol; 2010 Jul; 30(3):263-72. PubMed ID: 20577933
[TBL] [Abstract][Full Text] [Related]
7. Advances for the treatment of primary central nervous system lymphoma (review).
Yamanaka R; Tanaka R
Oncol Rep; 2004 Sep; 12(3):563-8. PubMed ID: 15289838
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
Ferreri AJ; Assanelli A; Crocchiolo R; Ciceri F
Hematol Oncol; 2009 Jun; 27(2):61-70. PubMed ID: 19247977
[TBL] [Abstract][Full Text] [Related]
9. [Neuropathologic evaluation of intrathecal prophylaxis results in adults with high grade non-Hodgkin's lymphomas].
Zyluk B
Ann Acad Med Stetin; 1997; 43():193-209. PubMed ID: 9471916
[TBL] [Abstract][Full Text] [Related]
10. Statistical and trial design considerations in central nervous system prophylaxis studies.
Smith JA; Glantz M
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S69-76. PubMed ID: 19660685
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
[TBL] [Abstract][Full Text] [Related]
12. Non-Hodgkin's lymphoma in AIDS.
Majchrowicz M
GMHC Treat Issues; 1995 Nov; 9(11):7-10. PubMed ID: 11362993
[TBL] [Abstract][Full Text] [Related]
13. Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A review of 36 cases.
Mead GM; Kennedy P; Smith JL; Thompson J; Macbeth FR; Ryall RD; Williams CJ; Whitehouse JM
Q J Med; 1986 Jul; 60(231):699-714. PubMed ID: 3763820
[TBL] [Abstract][Full Text] [Related]
14. Controversies in primary CNS lymphoma.
Abrey LE
Expert Rev Neurother; 2005 Jul; 5(4):459-64. PubMed ID: 16026229
[TBL] [Abstract][Full Text] [Related]
15. [Neuralgia of the trigeminal nerve as first symptom of a primary central nervous system lymphoma of non-Hodgkin's type].
Wentzky P; Berndt S
Fortschr Neurol Psychiatr; 2003 Feb; 71(2):67-71. PubMed ID: 12579469
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
Jönsson P; Höglund P; Wiebe T; Schrøder H; Seidel H; Skärby T
Anticancer Drugs; 2007 Sep; 18(8):941-8. PubMed ID: 17667600
[TBL] [Abstract][Full Text] [Related]
17. Primary non-Hodgkin's lymphoma of the central nervous system.
Chin HW; Chin RY; Mansouri A; Ampil FL; Bahrassa FS
J La State Med Soc; 1993 Jan; 145(1):21-4. PubMed ID: 8423411
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
Sancho JM; Orfao A; Quijano S; García O; Panizo C; Pérez-Ceballos E; Deben G; Salar A; González-Barca E; Alonso N; García-Vela JA; Capote J; Peñalver FJ; Provencio M; Arias J; Plaza J; Caballero D; Morado M; Feliu E; Ribera JM;
Eur J Haematol; 2010 Oct; 85(4):321-8. PubMed ID: 20528905
[TBL] [Abstract][Full Text] [Related]
19. [Ferritin in the cerebrospinal fluid as an early indicator of neuromeningeal involvement in patients with malignant lymphoma].
Aviles A; Gómez R; Salas J
Gac Med Mex; 1991; 127(3):249-52. PubMed ID: 1800218
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma.
Stern JI; Raizer JJ
Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S63-70. PubMed ID: 16274272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
